COVID-19

An Examination of School Reopening Strategies during the SARS-CoV-2 Pandemic | Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience | Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors

SARS-CoV-2 transmission at an overnight camp | Rapid Tests –
This website contains important information about rapid antigen testing for SARS-CoV-2. | In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19 | Acute SARS-CoV-2 infection impairs DC and T cell responses

Field-deployable, rapid diagnostic testing of saliva samples for SARS-CoV-2. | Age-Related Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19) | Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020

Two essential episodes of This Week in Virology: TWiV 641: COVID-19 with Dr. Anthony Fauci & TWiV 640: Test often, fast turnaround, with Michael Mina | Effect of Systemic Glucocorticoids on Mortality or Mechanical Ventilation in Patients With COVID-19 | Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report | Socio-demographic and epidemiological consideration of Africa’s COVID-19 response: what is the possible pandemic course? | COVID-19 in Africa: the spread and response

The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings | Test sensitivity is secondary to frequency and turnaround time for COVID-19 surveillance

FDA plays a critical role in protecting the United States from threats such as emerging infectious diseases, including the Coronavirus Disease 2019 (COVID-19) pandemic which has been caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). FDA is committed to providing timely guidance to support response efforts to this pandemic. FDA is issuing this guidance to assist sponsors in the clinical development and licensure of vaccines for the prevention of COVID-19.

Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19 | Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study | Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report | Tocilizumab treatment for Cytokine Release Syndrome in hospitalized COVID-19 patients: survival and clinical outcomes

SARS-CoV-2 shedding and seroconversion among passengers quarantined after disembarking a cruise ship: a case series | Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 (Press release) | Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants

COVID-19 Vaccine Developers Search for Antibodies That ‘First Do No Harm’ | Consensus summary report for CEPI/BC March 12–13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines